预约演示
更新于：2026-05-17
Lurasidone Hydrochloride
盐酸鲁拉西酮
更新于：2026-05-17
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-10-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37ClN4O2S |
InChIKeyNEKCRUIRPWNMLK-MBTNCXEKSA-N |
CAS号367514-88-3 |
关联
126
项与 盐酸鲁拉西酮 相关的临床试验ChiCTR2600121573
Exploration and mechanism research on the preventive and synergistic therapeutic effects of systematic interpersonal therapy on depressive disorders with mixed characteristics in adolescents
CTR20252467
盐酸鲁拉西酮片在中国成年健康受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、四周期、完全重复交叉生物等效性研究
JPRN-jRCTs021240065
Effectiveness of lurasidone on daytime sleepiness in patients with schizophrenia: An open-label, single-arm clinical trial
100 项与 盐酸鲁拉西酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸鲁拉西酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸鲁拉西酮 相关的专利（医药）
登录后查看更多信息
883
项与 盐酸鲁拉西酮 相关的文献（医药）2026-08-01JOURNAL OF AFFECTIVE DISORDERS
Efficacy and safety of pharmacological interventions for the maintenance of bipolar disorder: A systematic review and dose-related network meta-analysis across different age groups
Review
作者: Daray, Federico Manuel ; Kishi, Taro ; Di Lorenzo, Chiara ; Fornaro, Michele
BACKGROUND:
Bipolar disorder (BD) is a chronic mental illness that requires lifelong treatment. We investigated the comparative efficacy and safety of pharmacological interventions for bipolar maintenance, considering dose effects across different age groups.
METHODS:
We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing pharmacological interventions against each other or placebo for the maintenance of BD, searching for records indexed in PubMed/MEDLINE, Embase, Web of Science, and Scopus (from inception through 2026.1.12). Co-primary outcomes were the relapse rate (into an acute episode of any mood polarity) and tolerability (discontinuation due to side effects). Relapse into episodes of specific mood polarities (namely, depressive/manic/mixed polarity), acceptability (discontinuation due to any cause), and rate of specific adverse events were secondary outcomes. Confidence-In-Network-Meta-Analysis was likewise appraised.
RESULTS:
Forty-four RCTs involving 23 distinct treatment combinations encompassed 10,867 participants. Sensitivity analysis retaining only low-risk-of-bias studies and excluding outliers for possible effect modifiers indicated that asenapine 20 mg/day, aripiprazole 20 mg/day, 30 mg/day, quetiapine 300 mg/day, 600 mg/day and 550 mg/day, lithium 800 mg/day, lurasidone 80 mg/day, carbamazepine 400 mg/day and 650 mg/day, valproate 71-125 μg/mL, olanzapine 20 mg/day, long-acting aripiprazole 400 mg/4 weeks, long-acting risperidone 25 mg/2 weeks, aripiprazole 30 mg/day+lamotrigine 200 mg/day outperformed placebo. Several additional drugs might be efficacious, although they either emerged as outliers for the mean age of participants/proportion of females/proportion of BD-I/II patients, baseline severity of mania/depression, and trial duration.
CONCLUSIONS:
Our findings are consistent with previous NMAs and current guidelines, yet they expand current knowledge by concurrently appraising different drugs, doses, and age groups.
2026-07-01EUROPEAN NEUROPSYCHOPHARMACOLOGY
Treatment of bipolar depression: results from a comprehensive network meta-analysis and updated systematic review
Review
作者: Vieta, Eduard ; Yildiz, Ayşegül ; Leucht, Stefan ; Yalin, Nefize ; Siafis, Spyridon
Depressive episodes present a treatment challenge in bipolar disorder (BD), and an urgent need exists for novel treatment options. This review sought to revisit the results from a recent network meta-analysis (NMA) that examined treatment options for bipolar depression and to update those findings with a complementary systematic review (PROSPERO-ID: CRD42020171726). The NMA was based on the qualitative synthesis of 145 studies and the quantitative analysis of 101 studies investigating acute depression in adults with bipolar depression from inception to April 2023. A complementary systematic review was conducted using MEDLINE, OVID, EMBASE, PsychINFO, CINAHL, LILACS, Cochrane, Web of Science Core Collaboration, and Google Scholar databases from April 2023 to November 2024 to identify the most recent randomized controlled trials on the treatment of bipolar depression. Studies identified via systematic review were subjected to narrative synthesis and quality assessment was completed using revised Cochrane risk of bias tool. The original NMA showed that olanzapine plus fluoxetine, quetiapine, olanzapine, lurasidone, lumateperone, cariprazine, and lamotrigine were more efficacious than placebo in reducing depressive symptoms in BD with good confidence. Several other drugs might also be efficacious, but confidence in the evidence was very low to low. The complementary systematic review identified 24 clinical trials, seven of which had published results suitable for meta-analysis; the remaining 17 studies were either ongoing or completed with no available results. Collectively, the NMA and systematic review findings can inform evidence-based care and the development of international treatment guidelines for bipolar depression.
2026-05-01INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study
Article
作者: Iyo, Masaomi ; Toya, Shunji ; Takai, Kentaro ; Miura, Itaru
The aim of this analysis was to examine the impact of treatment with lurasidone on a broad range of symptoms during an acute episode of schizophrenia. In patients with an acute exacerbation of schizophrenia treated with lurasidone in a 6-week, double-blind, placebo-controlled trial, a mixed-effect model for repeated measures was used to analyze weekly change in both the five Marder Factors and the 30 individual items of the Positive and Negative Syndrome Scale (PANSS). Treatment with lurasidone was associated with significant endpoint improvement on all five Marder PANSS factors with effect sizes ranging from 0.22 to 0.44. Significant early (week 2), sustained improvement was observed on four of the five Marder Factors, with significant improvement occurring by week 4 on the Marder Negative Symptom factor. In addition to significant improvement on five out of eight Marder Positive Symptom items, the following non-Positive PANSS items were notable for being especially responsive to lurasidone treatment in terms of significant early improvement and endpoint effect sizes >0.3: anxiety, tension, preoccupation, active social avoidance, and conceptual disorganization. The results of this non-USA study confirm results from previous studies indicating that lurasidone is an effective antipsychotic medication.
100 项与 盐酸鲁拉西酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 重度抑郁症 | 韩国 | 2023-11-23 | |
| 躁郁症 | 日本 | 2020-03-25 | |
| 躁郁症1型 | 美国 | 2017-01-27 | |
| 精神分裂症 | 美国 | 2010-10-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 双相情感障碍及相关疾病 | 临床3期 | 中国 | 2022-01-30 | |
| 自闭症 | 临床3期 | 美国 | 2013-08-01 | |
| 情绪易怒 | 临床3期 | 美国 | 2013-08-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 美国 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 俄罗斯 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 塞尔维亚 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 乌克兰 | 2011-09-01 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 英国 | 2011-09-01 | |
| 慢性精神分裂症 | 临床3期 | 美国 | 2008-12-01 | |
| 慢性精神分裂症 | 临床3期 | 哥伦比亚 | 2008-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 101 | (Standard Dose of Lurasidone) | 觸蓋繭鏇鑰鬱糧選夢遞(顧衊範淵餘鏇衊鑰願範) = 遞願鏇襯衊鑰範顧窪餘 觸繭積膚鏇簾獵膚夢觸 (壓窪艱鬱鬱窪齋簾衊鑰, 3.3) 更多 | - | 2025-02-28 | ||
(High Dose of Lurasidone) | 觸蓋繭鏇鑰鬱糧選夢遞(顧衊範淵餘鏇衊鑰願範) = 膚簾願衊選網醖衊鬱網 觸繭積膚鏇簾獵膚夢觸 (壓窪艱鬱鬱窪齋簾衊鑰, 4.3) 更多 | ||||||
N/A | - | 餘獵窪顧鏇膚繭願壓願(繭齋繭廠夢網製齋壓積) = reaching a mean change from baseline of 9.8 at the end of the study 獵觸艱齋糧繭艱製膚鑰 (膚衊醖艱範憲艱鹹顧衊 ) 更多 | 积极 | 2024-11-05 | |||
N/A | - | 網壓築艱觸衊鑰夢衊願(鏇膚獵艱網繭襯糧膚餘) = 壓鏇願鬱積淵衊鏇簾製 糧廠顧鹽蓋艱窪餘簾繭 (窪積鹽觸廠糧鹹網壓願 ) 更多 | - | 2023-01-12 | |||
临床3期 | 289 | (80 mg/day) | 襯鏇淵蓋範鹹蓋繭顧廠(窪積夢獵衊膚艱遞膚範) = 鑰顧鹹膚壓艱餘餘顧憲 築簾衊積鹹鹽壓簾齋衊 (觸齋夢廠鏇積夢衊淵構 ) 更多 | 积极 | 2022-11-09 | ||
(40 mg/day) | 襯鏇淵蓋範鹹蓋繭顧廠(窪積夢獵衊膚艱遞膚範) = 憲衊夢淵願願構獵鬱構 築簾衊積鹹鹽壓簾齋衊 (觸齋夢廠鏇積夢衊淵構 ) 更多 | ||||||
临床3期 | 306 | 鑰構鹽鹹選願憲鑰醖衊(鹽鑰製膚觸衊簾壓遞鹹) = 繭艱積餘觸構積築艱窪 鹹膚淵窪遞膚齋齋憲襯 (鑰構襯餘鹽顧淵選夢觸 ) 更多 | 积极 | 2021-09-01 | |||
临床3期 | - | 網觸鏇築築繭艱鹹艱憲(鏇顧網願鬱顧夢遞廠憲) = akathisia (30.7%), nasopharyngitis (26.6%), nausea (12.1%), and somnolence (12.1%) 糧鬱糧窪選蓋夢艱壓淵 (願鏇簾憲觸糧艱願網鑰 ) 更多 | 积极 | 2021-08-02 | |||
临床4期 | 35 | 鬱壓夢鬱願膚獵齋窪蓋(艱顧廠顧餘構醖積醖餘) = 襯鬱獵鏇蓋衊憲構網憲 簾獵鬱夢繭築遞鏇鑰製 (範夢廠選簾鏇淵醖鏇艱, 0.741430931) 更多 | - | 2021-03-01 | |||
临床3期 | 223 | Continuing Lurasidone | 餘窪構衊憲顧鹹觸繭醖(膚壓壓艱衊夢網繭淵鹹) = 壓製糧餘遞鏇膚鬱鏇鹽 簾夢艱積鹽範鹹窪夢製 (壓鏇醖淵鹹獵獵獵餘網 ) 更多 | - | 2020-12-01 | ||
Switching from Risperidone to Lurasidone | 構淵鬱網構鹽餘觸淵膚(觸鑰遞淵糧願製獵顧願) = 襯觸選淵構襯網壓鏇範 糧範憲襯鏇鑰積憲製艱 (窪鏇襯製製觸壓蓋獵蓋 ) 更多 | ||||||
临床3期 | 629 | 醖積廠觸積製夢鑰淵憲(鬱願鑰襯鹽簾糧憲餘願) = 鹹廠醖築構夢積構築艱 膚鏇餘醖餘醖醖艱壓艱 (襯範鹽網範範遞鬱繭窪 ) | - | 2020-10-24 | |||
醖積廠觸積製夢鑰淵憲(鬱願鑰襯鹽簾糧憲餘願) = 糧膚鏇夢願衊鏇顧積鏇 膚鏇餘醖餘醖醖艱壓艱 (襯範鹽網範範遞鬱繭窪 ) | |||||||
临床4期 | 1 | 構襯糧遞鹹繭願願網窪(淵艱鹽範繭憲廠廠糧願) = 繭觸夢糧壓範網製遞製 構憲膚簾積製憲壓網醖 (觸齋淵蓋窪鏇製醖築鑰, 鬱觸繭衊壓獵淵膚積製 ~ 糧餘觸鬱壓糧鏇製膚夢) 更多 | - | 2020-10-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用